SIO Gene Therapies
15 articles about SIO Gene Therapies
-
Sio Gene Therapies, Inc. to File for Dissolution and Declare an Initial Liquidating Distribution of $0.435 Per Share
2/2/2024
Sio Gene Therapies, Inc. ("Sio") today announced that it expects to file a certificate of dissolution (the "Certificate of Dissolution") with the Secretary of State of the State of Delaware, as contemplated by the Plan of Complete Liquidation and Dissolution (the "Plan") previously approved by Sio's Board of Directors and stockholders, on February 7, 2024.
-
Sio Gene Therapies Announces Fiscal Third Quarter 2022 Financial Results
2/14/2023
Sio Gene Therapies Inc. (NASDAQ: SIOX) today provided financial results for its fiscal third quarter ended December 31, 2022.
-
Sio Gene Therapies Inc. Announces Board Approval of Plan of Complete Liquidation and Dissolution
12/14/2022
Sio Gene Therapies Inc. (Nasdaq:SIOX) today announced that its Board of Directors has determined, after extensive and careful consideration of potential strategic alternatives, that it is in the best interests of the Company and its shareholders to dissolve the Company and liquidate its assets, including its subsidiaries.
-
Sio Gene Therapies Announces Fiscal Second Quarter 2022 Financial Results
11/10/2022
Sio Gene Therapies Inc. provided financial results for its fiscal second quarter ended September 30, 2022.
-
Sio Gene Therapies Announces Fiscal First Quarter 2022 Financial Results
8/11/2022
Sio Gene Therapies Inc. (NASDAQ: SIOX) today provided financial results for its fiscal first quarter ended June 30, 2022.
-
The biotech industry has been looking for multiple sources of financing, and there has been speculation that big pharma might come to the rescue. But a recent report says that's unlikely.
-
Sio Gene Therapies Announces Fiscal Year 2021 Year-End Financial Results
6/14/2022
Sio Gene Therapies Inc. (NASDAQ: SIOX) today provided financial results for its fiscal year ended March 31, 2022.
-
Sio Gene has terminated its licensing deal with the UMass to develop and commercialize two gene therapy product candidates to focus on more potentially profitable projects.
-
Sio Gene Therapies Provides Corporate Update
4/27/2022
Sio Gene Therapies Inc. announced that it has provided the required notice to the University of Massachusetts to terminate its licensing agreement to develop and commercialize gene therapy product candidates, including AXO-AAV-GM1 and AXO-AAV-GM2, for the treatment of GM1 gangliosidosis and GM2 gangliosidosis, respectively.
-
Sio Gene Therapies Announces Corporate Updates and Fiscal Third Quarter 2021 Financial Results
2/11/2022
Sio Gene Therapies Inc., a clinical-stage company focused on developing gene therapies to radically transform the lives of patients with neurodegenerative diseases, provided corporate updates and financial results for its fiscal third quarter ended December 31, 2021.
-
Sio Gene Therapies to Present at the 18th Annual WORLDSymposium™ 2022
2/2/2022
Sio Gene Therapies Inc. announced that it will present data in an oral platform presentation and two poster presentations at the 18th Annual WORLDSymposium™ 2022, to be held February 7-11, 2022.
-
This week, two biotechnology firms announced new leadership, David Nassif, J.D., and Christophe Bourdon.
-
Sio Gene Therapies Announces Prioritization of Lead Gene Therapy Programs in GM1 and GM2 Gangliosidosis, Extension of Cash Runway, and CEO Transition
1/31/2022
Sio Gene Therapies Inc. today provided a corporate update announcing the prioritization of AXO-AAV-GM1 and AXO-AAV-GM2, its clinical stage AAV gene therapy programs for GM1 and GM2 gangliosidosis (Tay-Sachs/Sandhoff disease).
-
Oxford Biomedica announces update to agreement with Sio Gene Therapies
1/31/2022
Oxford Biomedica plc announced today that it was informed on Monday 31 January by Sio Gene Therapies (Sio) that Sio intends to return the global rights for AXO-Lenti-PD and that they intend to cease work on this gene therapy programme in Parkinson’s Disease.
-
Sio Gene Therapies Announces Corporate Updates and Fiscal Second Quarter 2021 Financial Results
11/12/2021
Sio Gene Therapies Inc. (NASDAQ: SIOX), a clinical-stage company focused on developing gene therapies to radically transform the lives of patients with neurodegenerative diseases, today provided corporate updates and financial results for its fiscal second quarter ended September 30, 2021.